Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-11801326-B2
Application number	US-202017064434-A
Country	US
Kind code	B2
Filing date	Oct 6, 2020
Priority date	Oct 15, 2012
Publication date	Oct 31, 2023
Grant date	Oct 31, 2023

Abstract

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A polymeric composition comprising:
a substantially stable biocompatible polymer comprising a reaction product of:
a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and
wherein the substantially stable biocompatible polymer is dissolved in a solution.

2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.

3. The polymeric composition of claim 2 , wherein the at least one aromatic ring includes at least one iodine atom.

4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.

5. The polymeric composition of claim 4 , wherein the non-physiological solution includes a water miscible solvent.

6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.

7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.

8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1, Seq. ID 2, Seq. ID 3, Seq. ID 4, Seq. ID 5, Seq. ID 6, Seq. ID 7, Seq. ID 8, Seq. ID 9, Seq. ID 10, Seq. ID 11, or Seq. ID 12.

9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.

10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2,4,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate and hydroxyethyl methacrylate.

11. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is insoluble in a physiological solution.

12. The polymeric composition of claim 1 , wherein the first monomer includes ionizable groups.

13. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer has a concentration of about 1% w/w to about 50% w/w.

14. The polymeric composition of claim 1 , wherein the reaction product is of between about 75% and about 98% 2-oxo-2-(1-oxo-1-(1-oxo-1-(2,4,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate, between about 2% and about 25% hydroxyethyl methacrylate, and less than 1% azobisisobutyronitrile.

15. The polymeric composition of claim 1 , wherein the reaction product is of between about 85% and about 98% 1-((2-(methacryloyloxy)ethoxy)carbonyloxy)ethyl 3,5-diacetamido-2,4,6-triiodobenzoate, between about 2% and about 15% hydroxyethyl methacrylate, and less than 1% azobisisobutyronitrile.

16. A vial including the polymeric composition of claim 1 .

17. A syringe including the polymeric composition of claim 1 .

18. A method of treating a vascular condition, the method comprising:
delivering the polymeric composition of claim 1 to a vessel in need thereof.

19. The method of claim 18 , wherein the delivering is through a catheter or a microcatheter.

20. The method of claim 18 , wherein the vascular condition is an aneurysm, an arteriovenous malformation, a fistula, a tumor, or a combination thereof.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Keeley Edward Michael
• Greene Rob
• Harris Clayton

Classifications

• A61L24/06 Primary

  obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)} · CPC title

• A61K49/0442

  Polymeric X-ray contrast-enhancing agent comprising a halogenated group · CPC title

• A61K49/12

  Macromolecular compounds · CPC title

• A61L24/001

  Use of materials characterised by their function or physical properties · CPC title

• A61L24/0015

  Medicaments; Biocides · CPC title